Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
The company said its ENERGY Phase 2/3 study of nipocalimab-aahu (IMAAVY) showed statistically significant hemoglobin improvements, according to a market report.
THE APEX TIMES
THE APEX TIMES
The regulator authorized an every-eight-weeks maintenance schedule for Ebglyss, a move that could broaden the drug’s fit for long-term management of moderate-to-severe atopic dermatitis.
THE APEX TIMES
Balbale, who had served as chief merchandising officer for about four years, exits as CVS reorganizes the interim leadership of its merchandising function.
THE APEX TIMES
After a steep slide in 2026, Pfizer’s shares are getting a fresh look from RBC Capital Markets, which shifted its rating to align with a more balanced risk-reward profile ahead of potential catalysts in the company’s pipeline.
THE APEX TIMES
RBC upgraded its stance on Pfizer, indicating stabilization in expectations for the rest of 2026, according to a market report citing a veteran analyst.
THE APEX TIMES
A Los Angeles jury awarded $32 million in a mesothelioma-linked talc trial, underscoring how product-liability litigation continues to compete with Johnson & Johnson’s growth priorities.
THE APEX TIMES
The approval lets patients receiving Ebglyss for moderate-to-severe atopic dermatitis move to an extended dosing schedule for long-term control, potentially reducing the number of injections needed each year.
THE APEX TIMES
HCA Healthcare said its first-quarter 2026 adjusted EBITDA came in weaker than expected, while the company also disclosed workforce cuts, sending its stock lower on the news.
THE APEX TIMES
The verdict stems from a lawsuit alleging pleural mesothelioma caused by years of exposure to asbestos-contaminated talc linked to the company’s baby powder products.
